Loading...
•
Mar 31
Allogene Q1 2025 Earnings Report
Allogene Therapeutics reported its first quarter 2025 financial results and business update.
Key Takeaways
Allogene Therapeutics reported a net loss of $59.7 million for the first quarter of 2025, with an EPS of -$0.28. The company ended the quarter with $335.5 million in cash, cash equivalents, and investments, and has extended its cash runway into the second half of 2027 through strategic cost realignment.
Nearly 50 sites activated across U.S. for the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL).
The Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) is on track for a mid-2025 start in rheumatology, with proof-of-concept data moved to 1H 2026.
Updated Phase 1 TRAVERSE Trial results for ALLO-316 in Renal Cell Carcinoma (RCC) will be featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Strategic cost realignment and prioritization efforts have extended the cash runway into the second half of 2027.
Allogene
Allogene
Forward Guidance
Allogene Therapeutics expects to extend its cash runway into the second half of 2027 due to strategic cost realignment. The company anticipates a decrease in cash, cash equivalents, and investments by approximately $150 million for 2025, with GAAP Operating Expenses expected to be around $230 million.
Positive Outlook
- Cash runway extended into the second half of 2027.
- Spend focused on advancing Cema-Cel/ALPHA3 and ALLO-329/RESOLUTION clinical trials to key inflection points.
- Targeted reductions in manufacturing operations provide key savings while preserving core capabilities.
- Strategic cost-realignment efforts prioritize high-impact, value-generating programs.
- Unmatched efficiencies of allogeneic platform reinforce confidence in approach.
Challenges Ahead
- Lymphodepletion selection and futility analysis shifted to 1H 2026 due to site-related factors.
- Proof-of-Concept Data for ALLO-329 moved to 1H 2026.
- Expected decrease in cash, cash equivalents, and investments of approximately $150 million for 2025.
- GAAP Operating Expenses expected to be approximately $230 million, including estimated non-cash stock-based compensation expense of approximately $45 million.
- Estimates exclude any impact from potential business development activities.